Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
BeOne wins FDA approval in lymphoma race
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
Astellas treatment offers new hope to a devastated rare disease community
Meeting the Customer Engagement Moment in Life Sciences with Agentic Operating Systems - SPONSORED CONTENT FROM SALESFORCE ACCENTURE
FDA to reconsider treatment for rare cancer after its surprise rejection
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Biotech M&A is accelerating. Track the deals that are happening here.
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
FDA revisits a rare cancer treatment it rejected a few months ago
